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PT regimens and settings. Few studies investigated effectiveness of pharmacolog-
ical interventions for improving strength and performance. No studies estimated
the incidence, prevalence, or direct or indirect cost of muscle atrophy/weakness in
TKA. CONCLUSIONS: The impact of muscle atrophy/weakness on the cost and
treatment of TKA is poorly defined; few rehabilitation strategies fully restore
strength and function. Future research may need to evaluate the contribution of
muscle atrophy/weakness to TKA disease burden and determine optimal interven-
tions for recovery of strength and function.
PSU9
INCREASED EFFICIENCY THROUGH PATIENT MANAGEMENT IN ORTHOPEDIC
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OBJECTIVES: The objective of this evaluation was to analyze the economic impact
of introducing the RRP – a program that optimizes all aspects of a patient’s journey
from pre-operative assessment to discharge and beyond, which improves patient
satisfaction of patients undergoing primary hip and knee arthroplasty, in the Nor-
wegian South-Eastern Regional Health Authority (SENRHA). METHODS: An eco-
nomic model was developed using empirical data from a retrospective evaluation
of the RRP at the public-run London based Hillingdon Hospital Trust. The model
compared the two scenarios pre- and post-implementation of the RRP where the
former scenario constituted the current clinical practice of the SENRHA and the
lattermodeled the impact of the RRP on the SENRHA by assuming transferability of
the Hillingdon results, as they are reproduced in a model developed by the Berkely
Partnership in cooperation with the hospital. The model used in this analysis syn-
thesizes the evidence from Hillingdon with Norwegian cost and LOS data. The
pre-RRP number of patients and LOS at the SENRHA were retrieved from the Nor-
wegian Patients Registry. Cost components including staff, theatre, prosthetics,
drugs, bed days, pathology and diagnostics were collected from publicly available
sources. Benefits were estimated using the Norwegian DRG-based public funding
system. The SENRHA is one of four regional Norwegian health authorities serving a
population base of 2.8 million inhabitants. RESULTS: The model predicts a 58%
reduction in LOS for patients undergoing primary hip and knee arthroplasty and
estimate a volume increase of 92% for arthroplastic surgeries. Due to a reduction in
average cost per case and increased capacity, the overall change in SENRHA‘s net
position is estimated to 70 million US dollars. CONCLUSIONS: The model suggests
that implementing the Rapid Recovery Programme in the Norwegian South-East-
ern Regional Health Authority (SENRHA) is highly cost effective.
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OBJECTIVES: Lumbar spinal fusion for treatment of spinal stenosis with back pain
and spondylolisthesis has potential for perioperative morbidity, adjacent segment
degeneration, and increased costs which have led to the investigation into less-
invasive alternative treatments. Analysis of two-year results from randomized,
controlled clinical study comparing coflex interlaminar stabilization surgery with
posterolateral spinal fusion (PLF) surgery for stenosis with spondylolisthesis dem-
onstrated clinical equivalence or superiority with coflex, and showed clear superi-
ority in perioperative outcomes. The objective of this study is to determinewhether
the actual cost of coflex procedures is favorable to PLF, as a result of decreased
resource utilization. METHODS: Actual cost of care data was available for 62 pa-
tients across 3 of the 20 sites that participated in the clinical trial comparing coflex
with PLF. Actual facility costs for each case were calculated as 2011 USD, reported
as OR costs, recovery room costs, implant costs, supplies, drugs, and medical
equipment. Assumptions of cost for implants included 1) $4-8,000 per coflex de-
vice, and 2) PLF implant costs range: $7-11,000 for 1-level, and $10-14,000 for 2-level.
RESULTS: Average blood loss, hospital stay, and OR time were substantially lower
with coflex. Based on actual costs to facilities examined, a 1-level coflex procedure
saved on average $8776 peri-operatively, compared with 1-level PLF. Similarly, a
2-level coflex procedure saved $4702 comparedwith 2-level PLF. For these patients,
%ODI improvement was similar among the 4 cohorts at 2 years: 1-level coflex
(59.5%), 1-level fusion (38.0%), 2-level coflex (63.3%), 2-level fusion (64.1%).
CONCLUSIONS: On average, 1-level coflex procedures saved $8776 per case, while
2-level coflex procedures saved on average $4702 compared with fusion, while
producing similar or improved clinical outcomes at 2 years. Our data suggest the
potential for substantial cost-savings with coflex interlaminar stabilization com-
pared with fusion in the treatment of spinal stenosis and spondylolisthesis.
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OBJECTIVES: Video-Assisted Thoratic Surgical (VATS) lobectomies and wedge re-
sections result in lower morbidity and shorter length of stay (LOS) than open tho-
racotomy. The impact of robotic-assisted VATS on clinical and economic out-
comes, however, has not been examined. This study compared hospital costs and
clinical outcomes for VATS lobectomies and wedge resections with and without
robotic assistance.METHODS: Using the Premier hospital database, patients aged
18 years with a record of thoracoscopic lobectomy (ICD-9 code 32.41), thoraco-
scopic segemental resection of lung (ICD-9 code 32.30), or thoracoscopic excision of
lesion or tissue of lung (ICD-9 code 32.20) between 2009 to Q2 2011 were identified.
Procedures utilizing robotic technology were identified if one of two conditions
weremet: (1) a robotic ICD-9 procedure code accompanied the procedure of interest
or (2) “text” fields in the hospital charge master file indicated use of robot. Data
were collected on intra-operative and post-operative complications, LOS, readmis-
sion rates, and total hospital cost for the procedures. Bivariate comparisons be-
tween VATS procedures with/without robotic assistance used MannWhiteny-U to
test for differences in median costs and surgery times. RESULTS: Of 15,502 patient
records analyzed, 96% (n14,837) were performed without robotic assistance. Us-
ing robotic assistancewas associatedwith highermedian per patient hospital costs
(not including robotic capital or service contract). Median cost of inpatient proce-
dures with/without robotic assistance was $22,331 versus $17,667 (p0.0001) for
lobectomies and $17,369 versus 13,574 (p0.0001) for wedge resections respec-
tively. Median inpatient surgery times were not significantly different for lobec-
tomy (4.03 versus 4.00) but where longer for wedge resection. Surgery hours for
robotic wedge resection versus non-robotic were 2.92 versus 2.25 (p0.0001), re-
spectively. Median LOS was similar across both groups. CONCLUSIONS: Based on
this analysis, robotic-assisted VATS for lobectomy and wedge resection appears to
have higher hospital costs and wedge resections have longer surgery times.
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OBJECTIVES: To compare clinical and economic outcomes for conventional lapa-
roscopic (LAP) and robotic assisted minimally invasive surgery for segmental
colectomies.METHODS: Using the Premier hospital database patients 18 years
of age having one of the following primary LAP colectomies performed in 2009 toQ2
2011 were identified: cecectomy, hemi colectomy, left hemi colectomy, and sig-
moidectomy. Those procedures utilizing robotic technology were identified if one
of two conditions were met: 1) A robotic ICD-9 procedure code accompanied the
primary procedure of interest, or 2) “text” fields in the hospital charge master file
indicated use of the robot. Patients were matched on laparoscopic versus robotic
colectomy using a propensity score on severity, certain demographic and hospital
characteristics, and 1:1 on type of procedure. The association between robot-as-
sisted colectomy and adverse events, hospital costs, surgery time, and length of
stay was examined. RESULTS: Of 25,758 patient records from 364 hospitals, 98%
(n25,210) of laparoscopic colectomieswere performedwithout robotic assistance;
2% (548) with robotic assistance. After matching, 1,066 patients remained, 533 in
each group. No significant differences existed between the matched cohorts for
major, minor and/or surgical complications. Use of the robot was associated with
statistically higher mean per patient hospital costs. Inpatient procedures with and
without robot assistance cost $17,445 vs. $15,447 (p0.0008) respectively. The anal-
ysis did not include capital costs or service fees associated with maintaining the
robot. Inpatient surgery times were significantly longer for robot-assisted proce-
dures thannon-robot procedures (4.37 vs. 3.34 hours; p0.0001). Length of staywas
similar. CONCLUSIONS: Findings reveal minimal clinical differences in peri and
post-operative events and length of stay. There were significant increases in cost
per case and OR time for robotic assisted versus conventional LAP procedures.
These results call into question the cost-effectiveness of this technology in these
procedures.
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OBJECTIVES: Perioperative red cell salvage (CS) – the process of collecting shed
blood during surgery and returning it to patients - reduces the need for allogeneic
blood transfusion, which results in fewer transfusion-related adverse events and
consequently more quality-adjusted life years compared to surgery without CS.
However, little is known about the cost of CS in pediatric surgery. Our objectivewas
to compare the societal costs associated with four transfusion strategies among
patients undergoing elective orthopedic or cardiac surgery in Children’s Hospital
Boston: 1) CS followed by autologous transfusion; 2) CS followed by allogeneic
transfusion; 3) autologous transfusion alone; and 4) allogeneic transfusion alone.
METHODS: A TreeAge © decision tree was used to conduct all comparisons (2010
dollars), threshold analyses, univariate and multivariate probabilistic sensitivity
analyses. The CS-related and blood processing direct, indirect and labor costs/
patientwere obtained from the hospital accounting records and the cost of a unit of
red blood cells (RBC), from nationally representative reports. Probabilities of blood
transfusion after CS and the number of RBC units returned via CS were obtained
from hospital utilization records. The probabilities and lifetime costs of a range of
infections and reactions caused by allogeneic transfusion were derived from pub-
lished sources. RESULTS: Average CS, blood processing and RBC unit costs were
$160, $1895 and $223, respectively. Average volume of blood returned via CS was
271cc, and the probability of needing transfusion after CS was 0.80. Cell salvage
with autologous blood transfusion ($1504) was least expensive, followed by CSwith
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allogeneic transfusion ($1512), autologous ($1899) and allogeneic transfusion
($1906) with differences persisting in sensitivity analyses. Cell salvage resulted in
net savings at a threshold of $556/patient. CONCLUSIONS:Use of CS, particularly
with autologous blood pre-donation appears cost-saving and cost-effective in pe-
diatric surgery and should be encouraged.
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OBJECTIVES: Surgical site infections (SSIs) associated with total knee arthroplasty
(TKA) have a significant negative impact on outcomes and hospital reimburse-
ment. Our study uniquely looks at the impact of patients having SSI in their initial
admissionwith downstream outcomes of readmission to assess the complete con-
sequences of TKA related SSI, beyond a single episode of care. METHODS: Thom-
son Medstat Marketscan® Database was used to identify patients having a TKA
(ICD9-CM procedure code 81.54) between January 2007 and December 2009. Pa-
tients experiencing infections were defined by ICD-9-CM codes 998.5x, 998.66 and
998.67 as their secondary diagnosis in their index admission and as their primary or
secondary diagnoses during their 90-day readmissions. Total SSI burden was as-
sessed by evaluating differences in length of stay (LOS) and costs relative to those
with no SSI in the 3 groups: 1) during the initial admission in patients developing
SSI; 2) during the 90-day post surgery for patients who had developed SSI in their
initial admission; and 3) in patients experiencing SSI in their postoperative period.
Generalized linear models adjusting for age, gender, region and p/a diabetes were
used to compute mean differences and 95% confidence intervals. RESULTS: Pa-
tients in group 1 developing SSI as a complication of TKA incur an additional LOS of
2.4 days (95%CI:2.2-2.6 days) and an extra $6360 costs (95%CI:$4610-$8100). Group 2
patients are at risk of 0.75more downstream readmissions, and incur an average of
0.51 days additional LOS (95%CI:0.17-0.85) and $1,160 additional payments (95%CI:
$130-$2180). Group 3 patients are at risk of 1.3 additional readmissions, and incur
an average additional LOS of 8.2 days (95%CI:8.0-8.4) and $21,830 (95%CI:$21,160-
$22,510) in additional payments. CONCLUSIONS: SSI associated with TKA in-
creases current and downstream burden by a factor of 1.3-8.0 times in terms of
readmission rates and additional LOS and provider payments.
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IMPACT OF COMPLICATIONS IN SOLID ORGAN TRANSPLANTS ON HOSPITAL
CHARGES AND LENGTH OF STAY
Jensen IS, Helm T, Cyr PL
Navigant, Inc., Boston, MA, USA
OBJECTIVES: Solid organ transplants (SOT) are expensive, and much of the cost is
incurred in the first 3 months of care to cover pre-transplant, procurement and pro-
cedural costs, which can reach $200,000 per transplant, and higher with complica-
tions. Delayed graft function (DGF) is a complication affecting 20-40% of kidney trans-
plants and is believed to result from ischemic reperfusion injury (IRI). The objective of
this analysis is to quantify the additional charges and length of stay (LOS) associated
with complications such as DGF. METHODS: Using 2008 Health Care Utilization
Project (HCUP) data, individuals with a recorded transplant procedure (ICD-9 CM:
07.94 (thymus); 33.50-33.52 (lung); 336 (heart-lung); 41.94 (spleen); 46.97 (intestine);
50.51 and 50.59 (liver); 52.80-52.83 (pancreas); 65.92 (ovary) were identified. The
mean hospital charges for individuals with and without a recorded complication
diagnosis (ICD-9 CM 996.80-996.89 and additionally for kidney patients a recorded
dialysis procedure 39.95) were compared using student’s t-test. RESULTS: The
number of SOTs (and complications) for eachorgan typewere: 4119 (21%) kidney, 1677
(17%) liver, 485 (28%) heart, and 264 (35%) lung. Heart-lung, intestine, pancreas and
spleenwere excluded from the analysis with100 transplants each. Kidney and liver
transplant patients with complications had significantly higher mean hospital
charges and LOS than thosewithout the complications: kidney ($209,503 vs. $160,997,
p0.001) and (7.0daysvs. 11.1days, p0.001), and liver ($460,351vs. $340,296, p0.001)
and (21.0 days vs. 31.6 days). Heart and Lung transplant patients had higher charges
than those without the complication diagnosis. The difference was not statistically
significant. CONCLUSIONS: Our results demonstrate that having to treat complica-
tions of transplants adds significantly to the cost of hospital care and LOS. There is
a need for a novel agent that may reduce IRI. Proactive management of patients
with risk of IRI may confer substantial savings to hospitals.
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OBJECTIVES: Evaluate the cost of care for patients undergoing posterolateral spinal
fusion (PLF) between on-label Si-CaP use and off-label rhBMP-2 use. It is hypothe-
sized that Si-CaP patients will have lower Total patient costs (cost of entire inpa-
tient hospitalization), lower supply costs, and lower Operating Room costs.
METHODS: Patients over age 18 having a PLF procedure (ICD9 codes 81.62, 81.63, or
81.64) and receiving Si-CaP or rhBMP-2 on day of procedure between January, 2006
and December 31, 2010 were selected. Comorbidities were identified using a mod-
ified Charlsonmethod. Patients with 9 ormore levels fused were excluded. Univar-
iate group comparisons weremade using chi-square and student t-tests. Multivar-
iate linear models were developed using both normal and log transformation.
Discharges with costs less than $1,000 or greater than $500,000 were excluded in
the normal multivariate models but were included in the log transformed models.
RESULTS: A total of 60,260 patients were initially identified. After applying exclu-
sion criteria 59,229 patients were available for analysis (98.3%). Univariate compar-
isons of Total Cost as well as OR and Supply costs were significantly lower for the
Si-CaP cohort (p  0.05). Adjusting for patient and hospital covariates also showed
statistically significant lower estimated mean costs for Si-CaP for all outcomes (p
0.001). Differences in estimatedmeans for Total Costswere lower for Si-CaP $8931
and $7582 using normal and log-transformed values respectively. Estimatedmeans
for Supply Costs showed similar results of $7255 and $5274 for normal and log-
transformed values respectively. Operating RoomCostswere also similar, $961 and
$809. CONCLUSIONS: After adjusting for patient and hospital covariates Si-CaP
patients had significantly lower Total Patient Costs. While Supply Costs showed
similar results they do not fully explain the reduction in Total Cost suggesting that
there are other cost advantages besides product acquisition cost. Further research
should consider cost of complications and readmission.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in prostate surgery patients with perioperative blood loss (PBL) to those who
did not experience perioperative blood loss (NPBL). METHODS: Males with inpa-
tient prostate surgery discharges (ICD-9-CM: 60.0, 60.12, 60.14, 60.15, 60.3, 60.5,
60.6X, 60.72, 60.73, 60.79, 60.8X, 60.93, 60.94) were identified from the Premier Per-
spective® Database (CY 2009 - Q2 of CY 2010). Discharges were categorized into the
PBL group if they had received at least one blood transfusion (ICD-9-CM: 99.02-
99.07; CPT: 36430, 35455) during the hospital stay, otherwise were included in the
NPBL group. Blood transfusionwas assumed to be an indicator for PBL. Groupswere
matched (1:1) on age, race and APR-DRG severity using propensity scores. Adjusted
estimates for costs (total and departmental), days of stay in hospital (LOS), ICU, and
operating room (OR) time in minutes were compared between the PBL and NPBL
groups using generalized linearmodel (GLM)with gamma distribution and log link.
RESULTS: A total of 18,681prostate surgery discharges were identified. Of those,
1176 (6.3%) required at least one blood transfusion perioperatively. Aftermatching,
1168 discharges were retained in each group for the final analysis. Adjusted mean
total costs were significantly higher for the PBL group compared to NPBL group
($16,757 vs. $12,712, p0.0001). Mean adjusted costs associated with room& board,
surgery and pharmacy between PBL and NPBL group and were also significantly
higher for the PBL group (all p0.05). Compared to the NPBL group, the PBL group
had higher mean LOS (5.8 days vs. 3.6 days), and longer OR time (232 minutes vs.
211 minutes) (both p0.05). CONCLUSIONS: Perioperative blood loss for prostate
surgery patients adds significant burden to hospital costs and resources. Adopting
strategies aimed at minimizing PBL during prostate surgery process may conserve
valuable medical resources.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in renal surgery patientswith perioperative blood loss (PBL) to thosewho did
not experience perioperative blood loss (NPBL).METHODS: Inpatient discharges for
renal surgery (ICD-9-CM:55.0X, 55.1X, 55.24, 55.3X-55.8X) were identified from the
Premier Perspective® Database (CY 2009-Q2 of CY 2010). Discharges were catego-
rized as PBL group if they had received at least one blood transfusion (ICD-9-CM:
99.02-99.07; CPT:36430, 35455) during the hospital stay, otherwise were included in
the NPBL group. Blood transfusion was assumed to be an indicator for PBL. Groups
were matched (1:1) on age, gender, race, CCI score, APR-DRG severity and elective
admission type using propensity score. Adjusted estimates for costs (total and
departmental), days of stay in hospital (LOS), ICU, and operating room (OR) time in
minutes were compared between PBL and NPBL groups using generalized linear
model (GLM)with gammadistribution and log link. RESULTS:A total of 27,573 renal
surgery discharges were identified. 4,885 (17.7%) of all the selected patients re-
quired at least one blood transfusion perioperatively. After matching, 4,699 dis-
chargeswere retained in each group for the final analysis. Adjustedmean total cost
were significantly higher for the PBL group compared to NPBL group ($48,583 vs.
$35,298, p0.0001). Mean adjusted costs associated with room & board, central
supply, surgery, pharmacy and laboratory and pathology between PBL and NPBL
group and were also significantly higher for PBL group (all p0.05). Compared to
NPBL group, PBL group had higher mean LOS (10.5 days vs. 7.9 days) and ICU days
(4.5 days vs. 3.6 days) and had longer OR time (227 minutes vs. 194 minutes) (all
p0.0001). CONCLUSIONS: Perioperative blood loss for renal surgery patients adds
significant burden to hospital costs and resources. Adopting strategies aimed at
minimizing perioperative blood loss during renal surgeries may be helpful.
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